

# Medication Shortage Communication

Information for health professionals in NSW public health organisations

## Adrenaline 1:10,000 (1 mg/10 mL) injection – Disruption to Supply

Date of notice	19 March 2020
Status	Current
Details of the product(s) affected	<p>ADRENALINE-LINK 1:10,000 1 mg/10 mL adrenaline (epinephrine) acid tartrate injection BP <b>ampoule</b> (AUST R: 119194)</p> <p>ASPEN ADRENALINE INJECTION adrenaline (epinephrine) 1 mg/10 mL solution for injection <b>ampoule</b> (AUST R: 162463)</p> <p>ADRENALINE-LINK 1:10,000 1 mg/10 mL adrenaline (epinephrine) acid tartrate injection BP <b>pre filled syringe</b> (AUST R: 210672)</p> <p>ADRENALINE AGUETTANT 1:10,000 adrenaline (epinephrine) (as acid tartrate) 1 mg/10 mL solution for injection <b>pre filled syringe</b> (AUST R: 282377)</p>
Reason for the shortage	Manufacturing issue
Date shortage notified or apparent	Disruption to supply between 12 Dec 2019 to 15 Jun 2020
Estimated resupply dates	<p>20 Mar 2020 (ASPEN ampoule)</p> <p>14 Apr 2020 (LINK pre filled syringe)</p> <p>5 May 2020 (AGUETTANT pre filled syringe)</p> <p>15 Jun 2020 (LINK ampoule)</p>
Main therapeutic applications	<ul style="list-style-type: none"> <li>Adrenaline (epinephrine) is a nonselective adrenergic agonist with a range of therapeutic uses</li> <li>Adrenaline (epinephrine) 1:10,000 (1 mg/10 mL) is used as an adjunct in cardiac arrest as well as for inotropic support in the acute heart failure, cardiogenic shock and septic shock</li> </ul>
Alternative agents	<p>Juno Pharmaceuticals has approval under section 19A of the Therapeutic Goods Act 1989 for an Irish brand of adrenaline (epinephrine) 1:10,000 <b>pre filled syringes</b>.</p> <p>Link Medical Products P/L has been approved to temporarily supply the European brand of Martindale adrenaline (epinephrine) 0.1 mg/mL (10mL) solution for IV injection <b>ampoule</b> under the Special Access Scheme (SAS) of the Therapeutic Goods Act 1989. Note that this product is originally manufactured in UK.</p>
Precautions associated with alternative products	<p>The European brand of Martindale adrenaline (epinephrine) 0.1 mg/mL (10mL) solution for IV injection <b>ampoule</b> is NOT labelled in English and there is no English translation of the Product Information available.</p>

	Local Drug and Therapeutics Committees should implement appropriate medication safety measures to reduce risk of error, prior to making them available for patient use.
Anticipated effect of shortage on clinical practice	Action to address the disruption to supply of adrenaline (epinephrine) 1:10,000 should be planned and implemented at a local level by the Drug and Therapeutics Committee.
Associated regulatory/policy issues	PD2013_043 Medication Handling in NSW Public Health Facilities
Key contacts	Clinical Excellence Commission (Medication Safety): <a href="mailto:CEC-MedicationSafety@health.nsw.gov.au">CEC-MedicationSafety@health.nsw.gov.au</a> HealthShare NSW (Clinical Product Manager - Statewide): <a href="mailto:Michael.Marquez@health.nsw.gov.au">Michael.Marquez@health.nsw.gov.au</a>

*This Communication is intended as a guide only and does not equate to expert opinion. Interpretation of recommendations should always be taken in context with the patient's current condition and formal clinical assessment. As the information in this publication is subject to review, please contact a medical or health professional before using this publication.*

*Whilst the information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the Information. The information may change without notice and the State of New South Wales is not in any way liable for the accuracy of any information printed and stored or in any way interpreted and used by a user.*